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bstract
bjectives: Allopurinol is a uric acid lowering drug used in the treatment of gout and the prevention of tumor lysis syndrome. Allopurinol and
ts active metabolite oxipurinol inhibit xanthine oxidase, which forms uric acid from xanthine and hypoxanthine. Therapeutic drug monitoring
s an important option for evaluation and optimization of allopurinol treatment in case of renal impairment, interaction with uricosuric drugs or
o verify patient adherence. In this study we developed and validated a simple quantitative assay using reverse phased high-performance liquid
hromatography (HPLC) with UV-detection as a method for quantification of allopurinol and oxipurinol in human serum in the presence of different
requently used drugs.
ethods: The HPLC–UV method uses a mobile phase consisting of sodium acetate (0.02 M; pH 4.5), at a flow rate of 1.0 mL/min. Allopurinol
nd oxipurinol are detected by UV-absorption at 254 nm with a retention time of 9.9 min for oxipurinol and 12.3 min for allopurinol. Aciclovir is
sed as internal standard.
esults: Validation showed for allopurinol lower and upper limits of quantification of 0.5 and 10 mg/L and for oxipurinol 1 and 40 mg/L,
espectively. The assay was linear over the concentration range of 0.5–10 mg/L (allopurinol) and 1–40 mg/L (oxipurinol). Intra- and inter-day
recision showed coefficients of variation <15% over the complete concentration range; accuracy was within 5% for allopurinol and oxipurinol.
ndogenous purine-like compounds were separated from allopurinol, oxipurinol and aciclovir with a resolution factor >1.5. Exogenous purine-like
ompounds and co-medication frequently used by gout patients did not hinder the analysis due to the dichloromethane washing step or to low
V-absorpion at 253 nm. Serum levels of 66 patients prescribed allopurinol 300 mg/day were determined using this HPLC–UV method. Measurederum allopurinol and oxipurinol concentrations in clinical practice showed large variability with a range of <0.5–4.3 mg/L for allopurinol and
1.0–39.2 mg/L for oxipurinol, respectively.
onclusion: We developed an easy-to-operate and validated HPLC–UV method for the quantification of allopurinol and oxipurinol in human
erum. This method was proven to be valid for samples of gout patients frequently using concomitant medications.
2007 Elsevier B.V. All rights reserved.
; Vali
aeywords: Allopurinol; Oxipurinol; Reversed-phase chromatography; Stability
. IntroductionAllopurinol is worldwide the mainstay of modern treatment
f gout and prevention of tumor lysis syndrome. Allopurinol,
∗ Corresponding author at: PharmD, Henri Dunantweg 2, 8934 AD Leeuwar-
en, The Netherlands. Tel.: +31 58 2866610; fax: +31 58 2866606.
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n isomer of hypoxanthine, and its active metabolite oxipurinol
alloxanthine) act by inhibiting xanthine oxidase, an enzyme
hich forms uric acid (urate) from xanthine and hypoxanthine.
Allopurinol can be administered either orally or intra-
enously. The oral bioavailability is about 67 to 90% with a
eak plasma concentration occurring within one hour; the vol-
me of distribution is approximately 1.6 L/kg [1]. Allopurinol
s principally metabolized by aldehyde oxidase to the active
ompound oxipurinol [2]. The peak plasma concentration of
M.K. Reinders et al. / Journal of Pharmaceutical a
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xipurinol occurs within 3–5 h. Mean elimination plasma half
ives ranges between 0.7 and 1.5 h for allopurinol and 18–40 h
or oxipurinol [1].
Allopurinol is excreted in urine for less than 10% unchanged
nd for 70% as oxipurinol; 20% is excreted in feces. In patients
ith renal impairment (creatinine clearance <80 mL/min [3]),
he maintenance dosage of allopurinol must be reduced to pre-
ent toxic effects related to increased oxipurinol serum levels
3,4]. When renal impairment is present, the initial allopuri-
ol dosage can be calculated based on the estimated creatinine
learance (Table 1) [3]. Optimization of individual allopurinol
osage can be done by targeting of the oxipurinol – steady state
serum concentrations [5–9] as advised in the product informa-
ion of allopurinol [5]. Reference serum oxipurinol values which
re considered therapeutic, range from 5 to 15 mg/L [9].
The renal excretion of oxipurinol is increased by co-
dministration of uricosuric drugs (e.g. probenecid and
enzbromarone) which are also used to decrease serum urate
evels, presumably by interaction at the URAT-1 transporter
10,11]. Combination of these drugs with allopurinol is fre-
uently used in patients with severe gout, although, optimization
f allopurinol dosage by measuring oxipurinol serum levels
ight be necessary. Another indication for therapeutic drug
onitoring (TDM) is to verify a patient’s adherence to the use of
llopurinol, which in general is reported to be a point of concern
12,13].
Several methods are described for the analysis of allopuri-
ol and oxipurinol in human serum. However, these published
ethods, using reversed phase high-performance liquid chro-
atography, might have several limitations [14–22]. For
xample, (1) lack of information on chromatographic inter-
erence on detection and quantification of the analytes by
oncomitant medications frequently used by gout patients; (2)
pper limits of quantification not covering the complete concen-
ration range as observed in clinical practice; and (3) absence of
tability data of allopurinol and oxipurinol in serum kept under
efrigerated conditions.
The objective of the present study was to develop and validate
new analytical method which enables measurement of allo-
urinol and oxipurinol in representative serum samples obtained
rom daily clinical practice.
. Materials and methods.1. Equipment
The chromatographic system consisted of a Merck-Hitachi
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00 autosampler (Perkin-Elmer, Wellesley, MA, USA), and a
pectroflow 757 variable absorbance detector (Kratos Analyt-
cal, Manchester, UK). Isocratic chromatographic separation
as performed on a reversed-phase LiChrospher 100 RP-18
olumn (5m; 250 × 4 mm; Merck, Darmstadt, Germany) con-
ected to a precolumn (LiChroCart Guard column 4–4 packed
ith Lichrospher 100 RP-18, 5m, 15 mm; Merck, Darmstadt,
ermany). The column temperature was maintained at 32.5 ◦C
Column heater 530; Alltech, Breda, The Netherlands).
The mobile phase consisted of a 0.02 M sodium acetate solu-
ion adjusted with acetic acid 30% to pH 4.5. All samples
nd standard solutions were chromatographed using this mobile
hase (flow rate 1.0 mL/min), an injection volume of 40l, and
V-detection at 254 nm. Time between injections was 25 min.
Data from each chromatographic run were processed using
otalChrom version 6.2 (Perkin-Elmer). Concentrations were
alculated from the peak height ratios in relation to the internal
tandard.
.2. Preparation of the mobile phase
The mobile phase was prepared by dissolving 2.72 g
aCH3COO·3H2O in 1000 mL distilled water (Versol Sterile
ater for irrigation, Laboratoire Aguettant, Lyon, France) and
orrecting the pH to 4.5 with acetic acid 30%. The mobile phase
as filtered and degassed before use.
.3. Preparation of standard solutions and samples
Stock standard solution of allopurinol (0.25 mg/mL) and
xipurinol (0.25 mg/mL) were prepared in distilled water. For
issolution 1% (v/v) 0.1 M sodium hydroxide was added. Aci-
lovir was dissolved in distilled water (0.1 mg/mL) and used as
n internal standard.
Stock solutions, stability samples and patient samples were
tored at −20 ◦C for 5 months.
Patient serum samples were prepared by adding aciclovir
olution (10L) as an internal standard to serum (100L) fol-
owed by mixing with 10% perchloric acid solution (50L).
fter cooling in the refrigerator for 10 min, dichloromethane
200L) was added. After shaking the mixture for 30 s, it was
entrifuged at 4000 rpm for 5 min. The aqueous supernatant
olution was analyzed with HPLC–UV.
Quality control standards and samples for stability testing
ere prepared by spiking blank pooled human serum with stock
tandard solutions and further processed as patient serum sam-
les.
.4. Method validation
We used a method validation program based on the crite-
ia developed by the European Agency for the Evaluation of
edical Products [23]. The limit of detection (LOD) was calcu-
ated using S/N = 3 and the lower limit of quantification (LLOQ)
as calculated using S/N = 10 (S/N = signal-to-noise ratio). Peak
eight was used for quantification. Linearity was examined over
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nd oxipurinol (1–40 mg/L) by testing nine different concentra-
ions in duplo. Linearity was analyzed using the lack of fit test
nd the goodness of fit test.
Selectivity was examined by studying the possible interfer-
nce of endogenous peaks and various co-medications with the
etermination of allopurinol, oxipurinol and the internal stan-
ard aciclovir. Acceptance criterion for lack of interference
as a resolution factor (Rs) between the peaks of allopuri-
ol, oxipurinol and internal standard and the peak of each
otentially interfering substance greater than 1.5. Substances
ere evaluated by preparing test solutions. Drugs and endoge-
ous substances studied were non-steroidal anti-inflammatory
rugs (acetylsalicylic acid, diclofenac, etoricoxib, ibupro-
en, indomethacine, naproxen, piroxicam, propyphenazone,
alicylic acid), cardiovascular drugs (bisoprolol, furosemide,
ydrochlorothiazide, lisinopril, losartan, metoprolol), endoge-
ous purines and xanthines test-solution (adenine, adenosine,
reatinine, hippuric acid, hypoxanthine, guanine, guanosine,
nosine, orotate, pseudo-uridine, thymine, uracil, urate, xan-
hine, xanthosine), xanthine derivatives (caffeine, paraxanthine,
heobromine, theofylline), acetaminophen, colchicine, met-
ormine, omeprazole and simvastatine.
The intra-day reproducibility was examined by analyzing
our independent preparations of each standard concentration,
ach injected five times, on the same day. Inter-day reproducibil-
ty was examined by analyzing four independent preparations
f each concentration, each injected five times, on three dif-
erent days within a period of 2 weeks. For each day, freshly
repared standard solutions were made. All standard solutions
ere prepared from an independent standard stock solution. The
alibration curve used for calculating patient samples was the
alibration curve determined from all data of the four separate
epetitions of intra-day reproducibility testing. These data were
tted using least sum of squares analysis. Criteria for acceptance
or each separate calibration curve were a regression coefficient
f >0.99 and a back-calculated concentration within 15% of the
espective target concentration.
Stability testing was based on the guidance of the Food
nd Drug Administration [24]. Stability of allopurinol 0.5 and
mg/L and oxipurinol 1 and 30 mg/L in human serum was stud-
ed by repeated, duplicate analysis. The solution was divided
nto 3 mL aliquots and kept frozen at −20 ◦C until the moment
f analysis. Samples were analyzed at week 0, 1, 2, 4, 10 and 22.
Furthermore, stability after two freeze-thaw cycles and after
4 h storage at room temperature was tested. Also, the stability of
tock solutions kept frozen at −20 ◦C for 5 months was verified.
.5. Chemicals
Dichloromethane and sodium acetate trihydrate were pur-
hased from Merck (Darmstadt, Germany). Allopurinol was
urchased from Bufa (Uitgeest, The Netherlands) and oxipurinol
rom Sigma–Aldrich (St. Louis, USA). Aciclovir was purchased
rom Mayne Pharma (Melbourne, Australia). Perchloric acid
as purchased from Mallinckrodt Baker (Phillipsburg, USA).
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.6. Patient samples
All consecutive patients visiting our outpatient department
f rheumatology from June 2005 to June 2006 were asked to
articipate in a study for evaluation of allopurinol 300 mg/day
ISRCTN21473387, http://www.controlled-trials.com). After 8
eeks treatment a single venous blood sample in anticoagulant-
ree containers was taken for determination of allopurinol and
xipurinol concentrations. After sampling, blood was directly
entrifuged and serum was kept frozen at −20 ◦C. Directly
rior to analysis, samples were processed as described above.
n case of serum concentrations of allopurinol or oxipurinol
bove the upper limit of quantification, samples were diluted
:1 with blank human serum and re-analyzed. All patient sam-
les were injected twice, comparable to standard and control
amples.




With the described method, Rs > 1.5 of allopurinol, oxipuri-
ol and the internal standard (aciclovir) was achieved (Fig. 1).
he retention times of oxipurinol, allopurinol and aciclovir are
.9, 12.3 and 17.7 min, respectively. Chromatographic perfor-
ance depended on column temperature. Because no cooling
evice and air conditioning was available, we used a col-
mn heater and evaluated column temperatures 30–40 ◦C.
est results were obtained with a column temperature of
2.5 ◦C. Recovery after deproteinizing and washing with
ichloromethane was estimated at 65% for allopurinol and 75%
or oxipurinol.
Chromatogram of blank human pooled serum sample is dis-
layed in Fig. 1a. Testing endogenous purine- and xanthine-like
ompounds showed several peaks (which were not further iden-
ified); important peaks for validation eluted at 8.9 min, 11.8 min
nd 19.4 min. Exogenous purine- and xanthine-like compounds
nd co-medication frequently used by gout patients did not show
ny peaks (due to the dichloromethane washing step or low
V-absorpion at 253 nm).
The LOD was calculated as 0.1 mg/L (4 ng) for allopurinol
nd 0.2 mg/L (8 ng) for oxipurinol and the LLOQ was calcu-
ated as 0.4 mg/L (16 ng) for allopurinol and 0.6 mg/L (24 ng)
or oxipurinol. The calibration curve for allopurinol and oxipuri-
ol was linear over the full concentration ranges of allopurinol
.5–10 mg/L and oxipurinol 1.0–40 mg/L.
Table 2 shows the results of the intra-day and inter-day
eproducibility, respectively. Coefficients of variation and accu-
acy for intra-day and inter-day reproducibility are within 15%
ver the concentration ranges of allopurinol 0.5–10 mg/L and
xipurinol 1–40 mg/L. On the basis of these results, using this
ethod the lower and upper limits of quantification of allop-
rinol are 0.5 and 10 mg/L, respectively, and the lower and
pper limits of quantification of oxipurinol are 1 and 40 mg/L,
espectively.
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Fig. 1. Chromatogram of analysis of allopurinol and oxipurinol in human serum. Retention times are 9.9 min for oxipurinol (1), 12.3 min for allopurinol (2), and
17.7 min for aciclovir (3; internal standard). (A) Blank pooled human serum; (B) allopurinol 0.5 mg/L and oxipurinol 1.0 mg/L; (C) allopurinol 4.0 mg/L and
oxipurinol 20 mg/L.
Table 2
Intra- and inter-day reproducibility for assay of allopurinol and oxipurinol in human serum by high-performance liquid chromatography
Drug Spiked (mg/L) Intra-day1 Inter-day2
Measured (mg/L)3 CV (%) Accuracy (%)4 Measured (mg/L)3 CV (%) Accuracy (%)4
Allopurinol 0.52 0.53 ± 0.01 2.1 1.4 0.53 ± 0.05 10.1 2.4
2.59 2.53 ± 0.11 4.2 −2.2 2.49 ± 0.10 3.9 −3.7
7.77 7.96 ± 0.11 1.3 2.5 7.74 ± 0.22 2.9 −0.4
10.4 10.3 ± 0.21 2.1 −0.5 10.4 ± 0.11 1.9 0.6
Oxipurinol 1.02 1.02 ± 0.04 3.6 0.3 1.07 ± 0.07 6.6 4.7
10.2 10.2 ± 0.14 1.4 −0.1 10.2 ± 0.28 2.7 −0.4
30.7 31.3 ± 0.32 1.0 1.8 30.5 ± 1.2 3.8 −0.6
41.0 40.4 ± 0.74 1.8 −1.5 41.7 ± 1.8 4.3 1.7
Legend: CV = coefficient of variation; 1 five repetitions each; 2 three separate days, five repetitions each day; 3 mean ± standard deviation; 4 relative deviation (%).
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Table 3
Stability results of allopurinol and oxipurinol in human seruma
Long-term stability (−20 ◦C) Allopurinol Oxipurinol
Reference (n = 5) 0.52 mg/L 7.89 mg/L 0.98 mg/L 30.7 mg/L
1 week (n = 2) −2.4%a 6.4% −0.7% −2.9%
2 weeks (n = 2) −15.1% −1.7% −4.9% 0.6%
4 weeks (n = 2) −0.8% −1.9% 5.8% −1.9%
10 weeks (n = 2) −4.6% −1.1% 7.4% −0.1%
22 weeks (n = 2) 13.9% −5.4% 1.1% 0.6%
Freeze-thaw stability
Reference (n = 4) 0.58 mg/L 8.52 mg/L 1.09 mg/L 31.3 mg/L
After 2 cycles (n = 4) −1.3% −2.6% 0.0% −1.4%
CV(%) 2.9% 1.6% 2.0% 1.5%
Autosampler stability
Reference (n = 5) 2.87 mg/L 10.6 mg/L










































a Stability results stated as relative deviation from reference (%); CV = coeffi
Results from the assays for studying long-term stability,
reeze-and-thaw stability and autosampler stability of allop-
rinol and oxipurinol are shown in Table 3. Samples show
cceptable long-term stability for at least 5 months, with dif-
erences between the baseline concentration and concentration
t follow-up <20% for the samples at the lower limit of quantifi-
ation and <15% for samples at the higher limit of quantification.
ood stability of allopurinol and oxipurinol was found after two
reeze-thaw cycles and after 24 h storage at room temperature.
urthermore, good stability of stock solutions was found for at
east 5 months (data not shown).
.2. Patient samples
Sixty-six blood samples were taken for determination of
llopurinol and oxipurinol concentrations. Patient characteris-
ics are given in Table 4. Measured serum concentrations show
arge variability, ranging from <0.5 to 4.3 mg/L for allopurinol
nd from <1.0 to 39.2 mg/L for oxipurinol. Median concentra-
ions are <0.5 mg/L for allopurinol and 11.5 mg/L for oxipurinol
43 patients with allopurinol serum concentration <0.5 mg/L).
able 4
atient characteristics for population included for determination of allopurinol
nd oxipurinol concentrationsa
haracteristics
umber of patients 66
ge (years) 58[13]
29–86
ale gender (%) 91





Prescribed daily allopurinol dose (mg) 300
a Data shown as mean[standard deviation] and range, unless stated otherwise.






















Our HPLC–UV method for the quantification of allopuri-
ol and oxipurinol in human serum samples is easy-to-operate,
alid, and advantageous over other methods described in litera-
ure.
Our method shows acceptable intra- and inter-day accu-
acy and precision over the allopurinol concentration range
.5–10 mg/L and oxipurinol concentration range 1–40 mg/L.
e did not investigate concentrations allopurinol >10 mg/L and
xipurinol >40 mg/L, because we considered it not clinically
elevant. Because allopurinol, and to a lesser extent oxipurinol,
re soluble in dichloromethane, no complete recovery was found
fter deproteinizing and washing. Endogenous serum peaks and
oncomitant medication frequently used by gout patients, did
ot interfere with the detection and quantification of allopurinol
nd oxipurinol in the current HPLC–UV method. The method
s not appiclable to patients using aciclovir or valaciclovir due
o the choice of internal standard.
Short-term stability of allopurinol and oxipurinol in human
erum kept frozen at −20 ◦C is shown for at least 5 months until
he moment of analysis, which enables collection of samples for
eriodical analysis in clinical practice.
Hyperuricemia is frequently accompanied by cardiovascu-
ar risk factors and the metabolic syndrome [25], which results
n hypertension, hyperglycemia and dyslipidemia. As a con-
equence, gout patients often have multiple drug use. Prior
esearch had several major limitations regarding (1) information
n interference of detection and quantification of allopuri-
ol and oxipurinol by endogenous compounds and frequently
sed co-medication by gout patients; (2) an upper limit of
uantification of oxipurinol that did not cover the complete
oncentration range expected to be obtained in patient sam-
les; (3) information about the stability of the analyte [14–22].
n addition, we used a washing step with dichloromethane to
xtract relatively hydrophobic substances, thereby reducing the
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Looking at the blank plasma chromatogram (Fig. 1a), several
eaks elute in the front. We did not identify these peaks individu-
lly, because we used a combined purine test-solution. However,
iving these and previous results [16,21], the front peaks might
nclude uric acid, hypoxanthine and xanthine, which can be of
nterest when a method for biochemical or metabolic purpose is
eeded.
The samples injected are very acidic (pH 0.5). Previously, it
as suggested to use ammonium sulfate for precipitation instead
f a strong acid solution (perchloric acid as in our method or
richloroacetic acid as described by Kramer et al. [22]), because
t was found that the low pH of the injected samples could shorten
olumn life [26]. Recently, Tada et al. did not find any column
eterioration using acidic samples and a buffered mobile phase
100 mM potassium phosphate; pH 4.0) [14]. Using a buffered
obile phase, we injected more than 300 samples as described
n the methods section. We did not experience any deterioration
n the performance of analyzing allopurinol and oxipurinol (nor
n the routine analysis of flecainide using the same column).
We used and validated this method with flow of 1 mL/min
esulting in a runtime of 24 min, which was rapid enough for our
urpose. When a more rapid method is preferred, a method might
e set up with a flow of 2 mL/min, as described previously [14].
To study the applicability of the validated method in clini-
al practice, a series of patient serum samples were analyzed for
llopurinol and oxipurinol concentrations. The serum concentra-
ions found are characterized by large inter-individual variation.
his might be explained by differences in therapy adherence,
ampling time compared to the last drug intake, variations in
enal function and variations in body composition. The upper
imit of quantification of our method covers all of the allopuri-
ol and oxipurinol concentrations found in the patient samples in
ur study. The LLOQ of allopurinol and oxipurinol was based
n the detection limit of our method. The LLOQ of oxipuri-
ol is sufficient for use in clinical practice with regards to the
herapeutic range (results below the lower limit of quantifica-
ion questions patient’s adherence to allopurinol). Because of the
hort elimination half-life of allopurinol of 0.5–2 h, serum trough
oncentrations found for allopurinol are predominantly below
he LLOQ. However, since peak serum levels of allopurinol
ange from 1–5 mg/L, measuring serum allopurinol can provide
dditional information about the dosing-sampling interval and
onsequently puts the measured serum oxipurinol concentration
n perspective.
. Conclusion
We developed an easy-to-operate and validated HPLC–UV
ethod for the quantification of allopurinol and oxipurinol in
uman serum for use in clinical practice. The method was shown
o be employable for the assay of samples of gout patients fre-
uently using concomitant medications.
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